Six-medicine composition as well as preparation method and application thereof

Abstract

The invention provides a six-medicine composition as well as a preparation method and application thereof. The six-medicine composition is prepared from the following components in parts by weight: 15 to 20 parts of spica prunellae, 10 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of herba scutellariae barbatae, 10 to 20 parts of herba hedyotidis diffusae, 12 to 15 parts of caulis bambusae in taeniam and 10 to 15 parts of exocarpium citri grandis. The components of the composition can coordinate and promote each other to achieve a synergistic effect, and the composition has a good anti-tumor effect, can effectively reduce the tumor weight of tumor-bearing mice and reduce the tumor volume of the tumor-bearing mice, and provides a new choice for prevention and / or treatment of brain glioma.

Description

Technical Field

[0001] The present invention relates to the field of biomedical technologies, and particularly to a six-herb composition, a preparation method thereof, and an application thereof. Background Art

[0002] Glioma is a common type of intracranial malignant tumor in clinical practice. Infiltration and growth of foreign substances in the brain can lead to increased intracranial pressure and changes in mental state, presenting clinical symptoms such as headache, diplopia, nausea, epilepsy, etc. Clinical diagnosis mainly relies on pathological examination. Currently, the main treatment method is to surgically remove the local mass and combine it with radiotherapy and chemotherapy. However, due to its mostly infiltrative growth and the abundance of intracranial blood vessels and nerve tissues, it is difficult to distinguish the boundaries between normal and diseased brain tissues, and it is difficult to completely remove the diseased tissues. After radiotherapy and chemotherapy, most patients experience adverse reactions such as fatigue, nausea and vomiting, and decreased liver function. Moreover, due to the existence of the blood-brain barrier, even for targeted drug therapy, the clinical trial efficacy is still not satisfactory. Glioma patients have a poor prognosis and a short survival period, which is a difficult problem in clinical diagnosis and treatment.

[0003] There is no clear description of "glioma" in ancient Chinese medical books. It is stated in "Collection of Thoughts on Traumatology" that "cancer tumors are not swellings formed by the binding of yin and yang vital qi, but are formed by the stasis of blood, turbid qi, and phlegm in the five zang-organs". According to its pathological nature, it can be classified into the categories of "abdominal mass", "accumulation", "tuberculosis", etc. in traditional Chinese medicine. And because the disease location is in the brain and is often accompanied by dizziness, blurred vision, and changes in mental cognition, it can also be summarized into the categories of "vertigo", "headache", "epileptic syndrome", etc. in traditional Chinese medicine theory according to its clinical manifestations. The spleen is the source of phlegm production. The glioma lesion is in the brain, with weakness of the spleen and stubborn phlegm sticking. The clear orifices are disturbed, the phlegm obscures and blocks, obstructing the brain collaterals, and the qi and blood stagnate. And "the head is the meeting point of all yang meridians", which is in charge of human's mental state and is most intolerant of the invasion of pathogenic qi. The qi transformation is unfavorable, the meridians are blocked, and stasis of blood and turbid stasis accumulate internally and invade the brain, resulting in dizziness and distending pain; insufficiency of yin blood fails to nourish the tendons and vessels, so the limbs are numb and weak. The nature of the glioma disease is deficiency in origin and excess in superficiality. The deficiency in origin is mostly manifested as insufficiency of qi and yin, and the excess in superficiality is that "phlegm coagulation", "blood stasis", "qi stagnation", and "heat toxin" interact with each other and are closely related to the liver and spleen. It is mostly caused by worry, anger, emotional discomfort, improper diet, and abnormal daily life, resulting in wind-phlegm blocking the collaterals, qi stagnation and blood stasis, and over time, phlegm and blood stasis interact and heat toxin accumulates internally.

[0004] EGFR amplification is a common type of glioma. Clinically, targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors is mostly adopted, but there are often adverse reactions such as drug resistance, skin rash, and gastrointestinal dysfunction in clinical trials, and the survival period and quality of life of glioma patients have not been significantly improved. In recent years, traditional Chinese medicine has played an important role in the prevention and treatment of tumors, and can effectively relieve neurotoxicity and reduce gastrointestinal discomfort reactions. Traditional Chinese medicine believes that the glioma lesion is in the brain, but is closely related to the liver and spleen, and cancer toxin is an important pathogenesis for the occurrence and development of glioma. Clinical diagnosis and treatment should run through the whole process.

[0005] Gliomas in the brain often occur concomitantly with pathogenic factors such as phlegm, dampness, stasis, and heat. They are not only pathological products that obstruct the flow of qi and blood but also pathogenic factors that consume the body's vital qi. In clinical diagnosis and treatment, it is necessary to distinguish between deficiency and excess and conduct stage-based treatment. At the initial stage of the disease, wind-phlegm and stasis often obstruct the brain. In clinical treatment, phlegm-resolving, stasis-removing, detoxifying, and mass-dissipating methods should be used first, with dispelling pathogenic factors taking precedence to better strengthen the healthy qi. Traditional Chinese medicines such as Gastrodia elata, Ligusticum chuanxiong, Bombyx batryticatus, and Pheretima aspergillum can be selected to guide the medicine into the brain. In the middle stage, the healthy qi and cancer toxins are in contention, and it is still possible to fight against pathogenic factors. Over time, stasis turns into fire. Traditional Chinese medicines such as Scutellaria barbata, Hedyotis diffusa, Prunella vulgaris, and Bambusa textilis can be selected to clear heat and detoxify, resolve phlegm and dissipate masses. In the late stage, the healthy qi is deficient, with phlegm-stasis intermingling and damp turbidity being mixed. Traditional Chinese medicines such as Astragalus membranaceus, stir-fried Atractylodes macrocephala, and Rhodiola rosea can be selected to tonify deficiency and strengthen the healthy qi, and protect the spleen and stomach. It should be further noted that the head is the meeting point of all yang meridians, and all the yang qi of the body ascends to the brain. Brain diseases are prone to transform into heat and fire, and radiotherapy is likely to damage yin and consume qi. After glioma surgery, patients are already deficient in qi and blood, and when invaded by heat pathogens, it is easy to cause phlegm coagulation and obstruction of collaterals, and internal stirring of liver wind. Current research has found that the amplification of human epidermal growth factor (EGFR) is a common type in adult high-grade gliomas. It has been found that EGFR is widely abnormally amplified and highly expressed in tumor patients. On the one hand, EGFR gene amplification usually leads to an increase in the expression level of EGFR protein, resulting in the activation of downstream RAS / RAF / MAPK, PI3K / AKT / MTOR, and STAT signaling pathways, leading to tumor cell proliferation and metastasis. On the other hand, tumor pathological products can also activate the MAPK signaling cascade pathway. Currently, there are mainly two types of clinical targeted drugs for EGFR: one is to block the activation of the tyrosine kinase region with monoclonal antibodies, and the other is tyrosine kinase inhibitors to competitively bind to the adenosine triphosphate site. Both block the relevant signal transduction pathways, but clinical studies have shown that these two types have side effects such as drug resistance and large toxic and side effects. In recent years, with the continuous in-depth research on tumors and the continuous promotion of the theory of "preventing disease," the characteristics of active ingredients in traditional Chinese medicines, such as reducing toxicity and increasing efficacy, reducing adverse reactions, and acting on multiple target sites, have been gradually recognized. Traditional Chinese medicine has great prospects in the prevention and treatment of tumors. Research has shown that heat-clearing and detoxifying traditional Chinese medicines such as Citrus reticulata, Prunella vulgaris, Hedyotis diffusa, and Scutellaria barbata can effectively downregulate the expression of EGFR and inhibit the proliferation, invasion, and motility of tumor cells. At the same time, network pharmacology and molecular docking techniques show that traditional Chinese medicines such as Citrus reticulata, Scutellaria barbata, and Hedyotis diffusa can reduce EGFR regulation and inhibit the proliferation of tumor cells. Summary of the Invention

[0006] The purpose of the present invention is to provide a six-herb composition, its preparation method, and application, so as to provide a new option for the prevention and / or treatment of gliomas in the brain.

[0007] To achieve the above purpose, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a six-herb composition, which is composed of the following components by weight: 15-20 parts of Prunella vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Caulis Bambusae in Taenia, and 10-15 parts of Exocarpium Citri Grandis. Preferably, the composition is composed of the following components by weight: 15-20 parts of Prunella vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Caulis Bambusae in Taenia, and 10-15 parts of Exocarpium Citri Grandis.

[0009] In a second aspect, the present invention provides the use of the above six-herb composition for preparing a medicament for treating glioma.

[0010] In a third aspect, the present invention provides a medicament for treating glioma, which comprises the above six-herb composition and a pharmaceutically acceptable carrier.

[0011] In a fourth aspect, the present invention provides a method for preparing a medicament for treating glioma, which includes taking the medicinal materials of Prunella vulgaris, dried tangerine peel, Scutellaria barbata, Hedyotis diffusa, Caulis Bambusae in Taenia, and Exocarpium Citri Grandis in proportion, adding 8 times the volume of water according to the prescription amount, heating for extraction, filtering, combining the filtrates, transferring all the medicinal liquids to a rotary evaporator by suction, concentrating it, and freeze-drying to obtain a freeze-dried powder.

[0012] Preferably, the dosage of each prescription is 20 g of Prunella vulgaris, 15 g of dried tangerine peel, 20 g of Scutellaria barbata, 20 g of Hedyotis diffusa, 12 g of Caulis Bambusae in Taenia, and 15 g of Exocarpium Citri Grandis. Each prescription is concentrated until the volume of the medicinal liquid is 100-150 ml.

[0013] Preferably, the freeze-drying process is as follows: the obtained medicinal liquid is precooled at -80°C overnight, then freeze-dried at -80°C for 72 hours, and ground into powder.

[0014] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0015] The present invention provides a scientific basis for the development of a drug for treating glioma using Prunella vulgaris, Citrus reticulata Blanco, Scutellaria barbata, Hedyotis diffusa, Bambusa textilis McClure, and Exocarpium Citri Grandis as raw materials, and has great application value. In the present invention, Prunella vulgaris is cold in nature and bitter and pungent in taste, mainly clearing heat and resolving phlegm, and can disperse the turbid qi in the head and eyes and relieve the poisonous sores caused by wind-heat; Citrus reticulata Blanco is warm in nature and bitter and pungent in taste, not only regulating qi and strengthening the spleen, drying dampness and resolving phlegm, but also coordinating with the pungent-dispersing qi of Prunella vulgaris to lead the other four herbs to the upper jiao and enter the brain; Scutellaria barbata and Hedyotis diffusa clear heat and detoxify, and promote diuresis, and specifically eliminate stubborn cancer phlegm; Bambusa textilis McClure is cool in nature and sweet in taste, and Exocarpium Citri Grandis is warm in nature and bitter and pungent in taste. The two are a pair of herbs for removing sticky phlegm and strengthening the acquired constitution; the whole formula has the effects of clearing heat and detoxifying, promoting blood circulation and removing stasis, and combining attack and supplementation. In the past, the compatibility of technologies only focused on promoting diuresis, detoxifying, and purging. The present invention first selects Prunella vulgaris and Citrus reticulata Blanco, both of which have bitter and pungent ascending and dispersing properties, and the guiding power of one cold and one heat is doubled, so that the medicinal effect can directly reach the brain. Scutellaria barbata and Hedyotis diffusa have been verified by multiple experiments to have anti-cancer and anti-glioma effects. Bambusa textilis McClure and Exocarpium Citri Grandis, one cool and one warm, can eliminate the sticky and adhesive properties of glioma. Therefore, each component can coordinate with each other and promote each other, playing a role of synergistic effect enhancement, having a good anti-tumor effect, and being able to effectively reduce the tumor weight of tumor-bearing mice and the tumor volume of tumor-bearing mice.

[0016] Through scientific research, the present invention finds that the six-herb composition can effectively reduce the tumor weight of tumor-bearing mice and the tumor volume of tumor-bearing mice, and has the effect of treating glioma. The six-herb composition can be developed into a drug for preventing and / or treating glioma. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Showing the body weight changes of mice administered with the six-herb composition of the present invention for 21 consecutive days;

[0018] Figure 2 Showing the changes in the tumor volume of tumor-bearing mice administered with the six-herb composition of the present invention for 21 consecutive days;

[0019] Figure 3 Showing the final tumor weight of tumor-bearing mice administered with the six-herb composition of the present invention for 21 consecutive days;

[0020] Figure 4 Showing the photographic records of the tumors of tumor-bearing mice administered with the six-herb composition of the present invention for 21 consecutive days. DETAILED DESCRIPTION OF THE INVENTION

[0021] The Liuwei Prescription is composed of 15 - 20 parts of Prunella vulgaris, 10 - 15 parts of Citrus reticulata Blanco, 10 - 20 parts of Scutellaria barbata, 10 - 20 parts of Hedyotis diffusa, 12 - 15 parts of Caulis Bambusae in Taeniam, and 10 - 15 parts of Exocarpium Citri Grandis. The Liuwei Prescription is an effective prescription for treating glioma, and it is formulated based on the clinical efficacy on the basis of the ancestral cancer - treating theory of the Wang family. The results of animal experiment research show that the traditional Chinese medicine compatibility prescription provided by the present invention has the effect of treating glioma. The present invention is derived from the core prescription for treating cancer, and other cancer - treating prescriptions can also be derived from this core prescription. The compatibility of this prescription is precise and the medication is fastidious. After being used by several generations, the curative effect is quite good. This medicine is easy to use, with reasonable compatibility, and the effect is safe and reliable, and has received wide acclaim in recent decades.

[0022] Next, the technical solutions in the embodiments of the present invention will be clearly and completely described in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative efforts belong to the scope of protection of the present invention.

[0023] In the description of the present invention, it should be noted that the orientation or positional relationships indicated by the terms "upper", "lower", "inner", "outer", "front end", "rear end", "both ends", "one end", "the other end", etc. are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and thus should not be construed as a limitation of the present invention. In addition, the terms "first" and "second" are only used for descriptive purposes and cannot be construed as indicating or implying relative importance.

[0024] In the description of the present invention, it should be noted that unless otherwise clearly specified and defined, the terms "installed", "provided with", "connected", etc. should be understood in a broad sense. For example, "connected" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be directly connected or indirectly connected through an intermediate medium, and it can be the communication inside two elements. For those of ordinary skill in the art, the specific meanings of the above terms in the present invention can be understood according to specific situations.

[0025] Embodiment

[0026] 1. Experimental materials

[0027] 1.1 Experimental animals:

[0028] C57BL / 6J mice (6 - 8 weeks old, weighing 18 - 20 g, male, SPF grade, certificate number: A202407080364) were purchased from Jiangsu Huachuang Xinnuo Medical Technology Co., Ltd. The animals were housed in the experimental animal house of Jiangsu Province Academy of Traditional Chinese Medicine (license number: SYXK (Jiangsu) 2021 - 0025). The environmental temperature was 22 - 25 °C, the relative humidity was 50 - 60%, and the light time was 8:00 - 20:00. Their free movement, eating, and drinking were ensured. After one week of adaptive feeding, the mice were modeled. All operations were carried out in accordance with the experimental animal welfare and ethics principles of Nanjing University of Traditional Chinese Medicine.

[0029] 1.2 Experimental medicinal materials and reagents:

[0030] The medicinal materials of the six - herb composition, Prunella vulgaris, Citrus reticulata Blanco, Scutellaria barbata, Hedyotis diffusa, Bambusa textilis McClure, Exocarpium Citri Grandis, and bevacizumab were all purchased from the pharmacy of Jiangsu Province Hospital of Integrated Traditional Chinese and Western Medicine.

[0031] 2. Preparation examples

[0032] Preparation of the six - herb composition and experimental drugs: Take the cut crude drugs of the six - herb composition that meet the requirements of the 2015 edition of the Chinese Pharmacopoeia, add 8 times the volume of water according to the prescription amount, extract by heating 2 times, 45 minutes each time, filter, combine the filtrates, transfer all the medicinal liquids to a rotary evaporator by suction, and concentrate it until the volume of the medicinal liquid is 100 - 150 ml; after pre - cooling at - 80 °C overnight, freeze - dry at - 80 °C for 72 hours, grind into powder, dispense with 50 mL centrifuge tubes, and store in a - 80 °C ultra - low temperature refrigerator for later use. 1 g of the freeze - dried powder obtained through the above process is equivalent to 9.18 g of crude drug.

[0033] 3. Biological experiments: Pharmacodynamic experiments of the six - herb composition on glioma model mice

[0034] 3.1 Experimental methods:

[0035] 3.1.1 Cell culture and sub - culture:

[0036] The GL261-luc cell line (purchased from Shanghai Anwei Biotechnology Co., Ltd.) was cultured in DMEM complete medium containing 10% fetal bovine serum and 1% penicillin-streptomycin antibiotics. The culture conditions were 37°C and 5% CO2. When the cell density grew to 80%-90%, passage was carried out. The medium was discarded, and the cells were washed twice with dPBS buffer (8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, pH 7.3, made up to 1000 mL with deionized water). 1 mL of trypsin was added and digested at 37°C. After 1 mL, 3 mL of complete medium was added to terminate digestion and gently pipetted down. After centrifugation at 1000 rpm for 3 min, the supernatant was discarded, and the cells were resuspended in 1 mL of DMEM complete medium.

[0037] 3.1.2. Establishment and grouping of subcutaneous tumor models of GL261-luc glioma in mice

[0038] GL261-luc glioma cells in the logarithmic growth phase were digested and counted, and the cell concentration was 2×10 7 / mL. The hair on the right side of the mouse was shaved off, and the skin was wiped with alcohol. GL261-luc (2×10 6 , 100 μL) was injected subcutaneously into the right side of the mouse. Five days after cell injection, the mouse tumor was measured with a vernier caliper. The measurement formula was: tumor volume = 0.5 × length × width × height. The mice were grouped according to their body weight and tumor size. After that, the mice were weighed and the tumors were measured every 3 days to detect changes in body weight and tumors.

[0039] According to the data on the 5th day after cancer cell injection, the mice were divided into a Vehicle group, a bevacizumab group (91 mg / kg, intravenous injection via the tail vein, administered once every two weeks), a low-dose group of six herbs (15.47 g crude drug / kg, this dose is approximately equivalent to the equivalent human dose in clinical trials, administered by gavage every day), a high-dose group of six herbs (46.41 g crude drug / kg, this dose is approximately 4 times the equivalent human dose in clinical trials, administered by gavage every day), a low-dose group of six herbs combined with bevacizumab (15.47 g crude drug / kg of six herbs by gavage, 91 mg / kg of bevacizumab by intravenous injection via the tail vein), and a high-dose group of six herbs combined with bevacizumab (46.41 g crude drug / kg of six herbs by gavage, 91 mg / kg of bevacizumab by intravenous injection via the tail vein).

[0040] 3.1.3. Detection of GL261-luc glioma subcutaneous tumor model in mice

[0041] The body weight and tumor changes of the mice were continuously detected. On the 27th day after modeling, the mice were sacrificed by taking blood from the eyeballs. The tumors and inguinal lymph nodes of the mice were dissected with forceps and scissors and immersed in pre-cooled PBS.

[0042] 3.1.4. Mouse tumor weighing and photographing

[0043] Take out the mouse tumors from PBS, dry them with absorbent paper, and weigh their mass on an analytical balance. Arrange the mouse tumors by group according to the weighing results and take pictures with a mobile phone.

[0044] 3.1.5. Data statistical method: All data were processed using GraphPad Prism 8.0. The results are expressed as mean ± standard deviation and the t-test was used for comparison between groups. P ≤ 0.05 indicates that the difference is statistically significant.

[0047] 3.2. Experimental results

[0048] 3.2.1. Effects of six herbs on the body weight of mice

[0049] The experimental results showed that the body weight of mice in each group showed a gradually increasing trend over time, and there was no significant difference between the drug-administered group and the blank group, indicating that treatment with six herbs and bevacizumab did not affect the body weight of mice, as Figure 1 shown.

[0050] 3.2.2. Effects of six herbs on the tumor growth of tumor-bearing mice

[0051] After continuously gavage-feeding mice with six herbs for 21 days, by recording the tumor volume of mice, it was found that treatment with bevacizumab, low-dose six herbs, high-dose six herbs, low-dose six herbs combined with bevacizumab, and high-dose six herbs combined with bevacizumab all inhibited the tumor growth of C57 tumor-bearing mice. And compared with single use of bevacizumab, high-dose six herbs combined with bevacizumab could significantly inhibit the tumor growth of mice, as Figure 2 shown, *p < 0.05.

[0052] 3.2.3. Effects of six herbs on the tumor weight of tumor-bearing mice

[0053] After continuously gavage-feeding mice with six herbs for 21 days and then dissecting the mice and weighing the tumors, the experimental results showed that: single administration of high-dose six herbs and high-dose six herbs combined with bevacizumab both reduced the weight of mouse tumors, and were significantly better than the low-dose six herbs and low-dose six herbs combined with bevacizumab groups, as Figure 3 shown, *p < 0.01.

[0054] 3.2.4. Effects of six herbs on the tumor size of tumor-bearing mice

[0055] After continuously administering the six herbs to mice by gavage for 21 days, the mice were dissected and the tumors were photographed and recorded. The experimental results showed that: when the high dose of the six herbs alone or the high dose of the six herbs combined with bevacizumab was administered, the tumors of the mice were visibly smaller, and were significantly smaller than those in the low-dose six-herb group and the low-dose six-herb combined with bevacizumab group, as Figure 4 shown.

[0056] Where the present invention is not elaborated, they are all well-known technologies to those skilled in the art.

[0057] Finally, it should be noted that: the above specific embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to the embodiments, those of ordinary skill in the art should understand that the technical solutions of the present invention can be modified and equivalently replaced without departing from the spirit and scope of the technical solutions of the present invention, and they should all be covered within the scope of the claims of the present invention.

Claims

1. A six-flavor medicinal composition, characterized in that: The composition is composed of the following components by weight: 15-20 parts of Prunella Vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Rhizoma Anemarrhenae, and 10-15 parts of Citrus aurantium.

2. The six-flavor medicinal composition according to claim 1, characterized in that: The composition is composed of the following components by weight: 15-20 parts of Prunella Vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Rhizoma Anemarrhenae, and 10-15 parts of Citrus aurantium.

3. Use of a six-flavor medicinal composition for preparing a drug for treating brain glioma, characterized in that: The six-flavor medicinal composition comprises 15-20 parts of Prunella Vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Rhizoma Anemarrhenae, and 10-15 parts of Citrus aurantium by weight.

4. A drug for treating brain glioma, characterized in that: The medicine comprises a six-flavor medicinal composition and a pharmaceutically acceptable carrier, wherein the six-flavor medicinal composition comprises, by weight, 15-20 parts of Prunella Vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Rhizoma Anemarrhenae, and 10-15 parts of Citrus aurantium.

5. The drug for treating brain glioma according to claim 4, characterized in that: The six-flavor medicinal composition comprises 15-20 parts of Prunella Vulgaris, 10-15 parts of dried tangerine peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Rhizoma Anemarrhenae, and 10-15 parts of Citrus aurantium by weight.

6. A method for preparing a drug for treating brain glioma, characterized in that: Take herba prunellae, tangerine peel, scutellaria barbata, oldenlandia diffusa, bamboo shavings, and tangerine peel in proportion, add 8 times the volume of water according to the prescription amount, heat for extraction, filter, combine the filtrate, transfer all the medicinal liquid to a rotary evaporator by suction, concentrate it, and freeze-dry it to obtain a lyophilized powder.

7. The method according to claim 5, characterized in that According to the prescription, the dosage of each prescription is 15-20 parts of Prunella Vulgaris, 10-15 parts of dried orange peel, 10-20 parts of Scutellaria barbata, 10-20 parts of Hedyotis diffusa, 12-15 parts of Rhizoma Anemarrhenae, and 10-15 parts of Citrus aurantium. Each prescription is concentrated until the volume of the liquid is 100-150ml.

Images